Notably, CXCR2 blockade inhibited tumor progression in various tumor models38–41 and restored the sensitivity of highly refractory tumor models to immunotherapy41–43, a testimony for a key role of PMN-MDSCs in immunosuppression and resistance to cancer immunotherapy. Here, CXCR2 is linked to neoplasm.